Extracorporeal Membrane Oxygenation System Market Size
Extracorporeal Membrane Oxygenation System Market reached US$ 574.64 million in 2025 and is expected to reach US$ 742.77 million by 2033, growing at a CAGR of 3.26% during the forecast period 2026-2033.
An extracorporeal membrane oxygenation system (ECMO), a life support machine, is used to treat various heart and lung diseases. The main purpose of an extracorporeal membrane oxygenation system is to provide enough oxygen to the body when the heart and lungs are not functioning properly. This machine is used worldwide to treat lung cancer and chronic disorders.
Extracorporeal Membrane Oxygenation System Market Scope
| Metrics | Details |
| Market CAGR | 3.26% |
| Segments Covered | By Type, By Applications, By Modality Type, By Age Group, By Component, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Extracorporeal Membrane Oxygenation System Market Dynamics
Rising prevalence rates of lung cancer, increasing geriatric population, and improvements in ECMO technology are the major factors driving the global extracorporeal membrane oxygenation system market.
The rising technological advancements and increasing novel product launches are expected to drive the market’s growth.
The extracorporeal membrane oxygenation system market is driven by various factors such as rising technological advancements, an increasing geriatric population, and improvements in ECMO technology are expected to be driving forces for the ECMO system market. The market’s growth can also be attributed to the rising number of ECMO centers, conferences, and training programs to increase awareness about the technology.
Moreover, the availability of technologically advanced devices by key players is also expected to play a vital role in the market’s growth. Rising government funding and increasing healthcare expenditure to treat chronic diseases will boost market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.
Another driving factor for the extracorporeal membrane oxygenation system market is the high adoption rate of ECMO techniques for lung transplantation. Thus, increasing awareness about extracorporeal membrane oxygenation techniques among patients and hospitals will provide market players with better opportunities in the future. Various novel product launches are also contributing to the growth of the market. For instance, in Jan 2021, Eurosets, an advanced medical devices developer and manufacturer, announced the commercial release (out of the USA) of its ECMOlife system for extracorporeal life support. This device has been clinically evaluated, supporting critically ill patients for around 400 days with 27 days of longest individual treatment.
High costs associated with extracorporeal membrane oxygenation systems are expected to hamper market growth.
The high cost of these systems and machines is the main factor responsible for restraining the market. This therapy takes much time, and many medical professionals team up for observation and care of a patient during the procedure; this gradually increases the cost.
Extracorporeal Membrane Oxygenation System Market Segmentation Analysis
The modality type segment is expected to grow at the fastest CAGR during the forecast period (2026-2033)
The modality type segment is the highest market holder in the global extracorporeal membrane oxygenation system market. Based on modality type, the global extracorporeal membrane oxygenation system market is segmented into Veno-venous (VV), Veno-arterial (VA), and Arterio-venous (AV). These modalities provide hemodynamic support and facilitate gaseous exchange in patients with cardiac or respiratory failure. Among these, Veno-venous (VV) segment is expected to account for the largest share of the market. The large share of this segment is mainly attributed to the high incidence of respiratory failure, rising lung transplants, and technological advancements. According to the U.S. National Institute of Health (NIH), a combination of veno-venous and veno-arterial is used in specific cases, such as cardiogenic shock.
The modality type segment dominates the market due to the demand for these systems and rising global respiratory diseases. The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in Oct 2021, Getinge announced the launch of its novel Rotaflow II extracorporeal life support system with the latest concept and various smart features. It can be used for ven-venous as well as for veno-arterial extracorporeal membrane oxygenation. Veno-venous ECMO provides therapy for patients suffering from severe pulmonary insufficiency where other conventional ventilation strategies do not work and are insufficient.
Extracorporeal Membrane Oxygenation System Market Geographical Share
North America holds the largest market share in the global extracorporeal membrane oxygenation system market.
North America dominates the global extracorporeal membrane oxygenation system market, primarily According to the World Health Organization (WHO), in 2020, around 251 million people suffered from Chronic obstructive pulmonary disease (COPD) worldwide. Attributed to the rising number of people suffering from cardiac and respiratory disorders.
Increasing expenditure on healthcare and raising awareness among people are also contributing to the market’s growth in this region. Advancement of technology in the ECMO systems and machines., increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the extracorporeal membrane oxygenation system market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in Apr 2020, LivaNova Plc., an innovative medical technology company, announced that the Bi-Flow extracorporeal membrane oxygenation cannula (ECMO) received CE Mark approval for the extracorporeal membrane oxygenation procedures where femoral artery cannulation is applied.
Extracorporeal Membrane Oxygenation System Market Companies and Competitive Landscape
The sinus dilation devices market is moderately competitive with local and global companies’ presence. MAQUET Holding B. V. & Co. KG, Medtronic plc, LivaNova PLC., XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical Inc, Fresenius Medical care AG & Co. KGaA, EUROSETS S.r.l. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in May 2022, LivaNova Plc, a medical product production company, acquired ALung Technologies Inc., a low-flow extracorporeal carbon dioxide removal technologies provider for acute respiratory failure patient treatment.
Medtronic Plc.
Overview: Medtronic is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. It was established in 1949 and is headquartered in Dublin, Ireland. It is operational in around 140 countries and employs over 90,000 people.
Product Portfolio:
NAUTILUS ECMO OXYGENATOR: This ECMO oxygenator has a path of flowing that is transverse with a circular profile. Transverse flow reduces the surface contact area and achieves lower blood pressure drop. It is circular, removing the low flow and stasis in corners.
Key Developments in the Extracorporeal Membrane Oxygenation System Market
May 2026: Medtronic received CE Mark for the VitalFlow™ Transport Frame Air and Ground (AG), expanding the VitalFlow ECMO System for inter-hospital transport. The accessory is designed to support ECMO patients during air and ground transfers between medical facilities, extending the system’s mobility capabilities.
- March 2026: Getinge received CE Mark for Cardiohelp II, its next-generation extracorporeal life support (ECLS) system. The system introduces advanced monitoring, guided workflows, integrated electronic gas blending, trend analysis and a compact, lightweight design aimed at improving ECMO usability and mobility.
- January 2026: Getinge advanced its Cardiohelp II regulatory program following its Q4 2025 CE-mark application. The company identified Cardiohelp II as a next-generation ECMO platform and outlined plans for further regulatory submissions, supporting the transition toward a more advanced transportable ECLS system.
- November 2025: Getinge continued development of its Cardiohelp ECMO platform with next-generation Cardiohelp II technology. The system combines transportability with enhanced monitoring, workflow guidance and decision-support capabilities, targeting more streamlined management of complex ECLS procedures.
Why Choose DataM?
- Technological Innovations: Explores advancements in extracorporeal membrane oxygenation (ECMO) systems, including compact and portable ECMO platforms, centrifugal blood pumps, integrated oxygenators, advanced monitoring and sensing technologies, integrated gas-blending systems, and digitally connected ECMO platforms designed to improve mobility, workflow, patient monitoring, and cardiopulmonary support. Leading systems increasingly emphasize portability and rapid deployment for intensive care, emergency medicine, cardiac surgery, and intra- or inter-hospital patient transport.
- Product Performance & Market Positioning: Evaluates ECMO systems based on critical performance parameters such as blood-flow management, oxygenation and carbon-dioxide removal, pump performance, oxygenator efficiency, pressure monitoring, safety features, portability, battery support, circuit configuration, monitoring capabilities, and duration of use. The analysis highlights how leading manufacturers differentiate through compact system design, integrated components, transport capability, workflow ergonomics, and solutions for respiratory and/or circulatory support.
- Real-World Evidence: Highlights the use of ECMO across intensive care, emergency medicine, cardiology, cardiac surgery, and patient transport for patients experiencing severe respiratory or cardiac failure. It evaluates applications including venovenous ECMO for respiratory support, venoarterial ECMO for circulatory support, extracorporeal cardiopulmonary resuscitation, and ECMO-supported transport, while incorporating evidence and clinical guidance from the Extracorporeal Life Support Organization (ELSO).
- Market Updates & Industry Changes: Tracks important developments across ECMO technology and clinical practice, including next-generation portable systems, improvements in monitoring and interoperability, advances in ECMO training and competency assessment, new clinical guidelines, transport-oriented solutions, and developments aimed at improving usability and patient management. ELSO's updated training guidance emphasizes standardized curricula, simulation, competency-based assessment, team training, and continuing education for ECMO professionals.
- Competitive Strategies: Analyzes how ECMO manufacturers strengthen their market position through product innovation, integrated pump-and-oxygenator platforms, portability, workflow improvements, digital connectivity, clinical education, and expansion of applications across respiratory and circulatory support. Competitive differentiation increasingly centers on creating compact, versatile systems that can be rapidly deployed and supported across critical-care and transport environments.
- Pricing & Market Access: Explains pricing and market-access differences based on ECMO system configuration, pump and oxygenator technology, disposable circuit requirements, monitoring capabilities, intended duration of support, portability, accessories, and service or training requirements. It also examines procurement through hospitals, intensive-care units, cardiac centers, ECMO programs, specialized critical-care providers, and medical-device distribution networks.
- Market Entry & Expansion: Identifies opportunities associated with the growing clinical use of ECMO for severe respiratory and circulatory failure, expansion of ECMO-capable centers, demand for transportable life-support systems, development of standardized ECMO training, and broader adoption of advanced monitoring and connected technologies. It also evaluates expansion strategies such as regional distribution, clinical partnerships, physician and ECMO-specialist education, product localization, and development of compact systems suitable for wider critical-care deployment. ELSO continues to develop and update guidance covering patient care, circuits, transport, training, and specialized ECMO applications.
The global extracorporeal membrane oxygenation system market report would provide access to approx. 45+market data table, 40+figures and 200 (approximate) pages.
Target Audience
- Hospitals & Healthcare Systems
- ECMO Centers & Critical Care Units
- Cardiac & Cardiothoracic Surgery Centers
- Intensive Care & Emergency Medicine Providers
- ECMO System & Extracorporeal Life Support Manufacturers
- Medical Device & Cardiopulmonary Support Companies
- ECMO Pump, Oxygenator & Circuit Manufacturers
- Healthcare Equipment Distributors & Suppliers
